Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug shows promise for blood cancer in small japanese study

NCT ID NCT05673460

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 27 times

Summary

This early-phase study tested a drug called nemtabrutinib in 7 Japanese adults with certain blood cancers (like leukemia or lymphoma) that had not responded to prior treatments. The main goals were to check safety, side effects, and how the drug moves through the body. Researchers also looked for early signs that the drug might help control the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MATURE B-CELL NEOPLASMS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Chiba Cancer Center ( Site 0005)

    Chiba, 260-8717, Japan

  • Kindai University Hospital ( Site 0006)

    Sayama, Osaka, 589-8511, Japan

  • Kyushu University Hospital ( Site 0008)

    Fukuoka, 812-8582, Japan

  • Nagoya University Hospital ( Site 0003)

    Nagoya, Aichi-ken, 466-8560, Japan

  • National Cancer Center Hospital East ( Site 0002)

    Kashiwa, Chiba, 2778577, Japan

  • Okayama University Hospital ( Site 0007)

    Okayama, 700-8558, Japan

  • Yamagata University Hospital ( Site 0001)

    Yamagata, 990-9585, Japan

Conditions

Explore the condition pages connected to this study.